Fused in sarcoma regulates DNA replication timing and progression

Weiyan Jia[1], Mark Scalf[2], Peter Tonzi[4], Robert J. Milliken[2], Sang Hwa Kim[1], William Guns[1], Lu Liu[3], Adam Mastrocola[1], Lloyd M. Smith[2], Tony T. Huang[4] and Randal S. Tibbetts[1]

[1]Department of Human Oncology
University of Wisconsin School of Medicine and Public Health
1111 Highland Ave
Madison WI 53705

[2]Department of Chemistry
University of Wisconsin-Madison
1101 University Ave
Madison, WI 53706

[3]Department of Biostatistics and Medical Informatics
University of Wisconsin School of Medicine and Public Health
1300 University Ave, Madison, WI 53706

[4]Department of Biochemistry and Molecular Pharmacology
New York University Langone Health
450 East 29th St
New York, NY 10016

Abstract

Fused in sarcoma (FUS) encodes a low complexity RNA-binding protein with diverse roles in transcriptional activation and RNA processing. While oncogenic fusions of FUS and transcription factor DNA-binding domains are associated with soft tissue sarcomas, dominant mutations in FUS cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS has also been implicated in DNA double-strand break repair (DSBR) and genome maintenance. However, the underlying mechanisms are unknown. Here we employed quantitative proteomics, trancriptomics, and DNA copy number analysis (Sort-Seq), in conjunction with *FUS*$^{-/-}$ cells to ascertain roles of FUS in genome protection. FUS-deficient cells exhibited alterations in the recruitment and retention of DSBR factors BRCA1 and 53BP1 but were not overtly sensitive to genotoxins. FUS-deficient cells exhibited reduced proliferative potential that correlated with reduced replication fork speed, diminished loading of pre-replication complexes, and attenuated expression of S-phase associated genes. FUS interacted with replisome components, including lagging strand synthesis factors, but did not translocate with active replication forks. Finally, we show that FUS contributes to genome-wide control of DNA replication timing. Alterations in DNA replication initiation and timing may contribute to genome instability and functional defects in mitotically active cells harboring disease-associated FUS fusions

Introduction

Fused in sarcoma (FUS, also referred to as translocated in liposarcoma, TLS) is a member of the FET (FUS, EWSR1, TAF15) family of RNA- and DNA-binding proteins that play important roles in transcription and splicing (Shang and Huang, 2016; Tan and Manley, 2009). Originally described as an oncogenic fusion to the CHOP transcription factor in myxoid liposarcoma (MLS) (Crozat et al., 1993; Rabbitts et al., 1993), *FUS*, rose to prominence with the discovery that inherited and de novo mutations in its open-reading frame cause dominant forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (Corrado et al., 2010; Kwiatkowski et al., 2009; Vance et al., 2009). Although the underlying mechanisms are still unclear, the preponderance of ALS/FTD-associated mutations in FUS interfere with its nuclear import and folding, leading to the accumulation of cytosolic FUS aggregates that disrupt cellular function through loss- and gain-of function mechanisms impacting protein translation and nuclear transport among other processes (Dormann et al., 2010; Kamelgarn et al., 2018; Ling et al., 2019; Lopez-Erauskin et al., 2018; Shang and Huang, 2016).

FET proteins share a common domain structure that includes an N-terminal low-complexity domain (LCD), a Gly-rich region, one or more arginine/glycine-rich (RGG) domains, an RNA recognition motif (RRM) with RNA- and DNA-binding activity, a zinc-finger domain, and a carboxyl-terminal PY-type nuclear localization signal that interacts with Transportin nuclear import receptors that are essential for proper FUS folding (Dormann et al., 2010; Hofweber et al., 2018; Qamar et al., 2018; Tan and Manley, 2009; Yoshizawa et al., 2018). The LCD is also of particular interest as it exhibits strong transcriptional coactivation potential *in vitro* and the fusion of this domain to the CHOP DNA binding domain drives gene deregulation and oncogenesis in MLS (Tan and Manley, 2009; Zinszner et al., 1994). The LCD also mediates protein-protein interactions and participates in FUS oligomerization and liquid demixing (Han et al., 2012; Kwon et al., 2013; Qamar et al., 2018; Schwartz et al., 2013; Sun et al., 2011) that may be central to its normal roles in transcription and splicing and pathologic roles in ALS/FTD (Shang and Huang, 2016).

In addition to their accepted roles in RNA processing, several lines of evidence support a role for the FET proteins in the cellular DNA damage response (DDR). FUS participation in the DDR was first inferred from chromosome instability and mild radiosensitvity phenotypes of *FUS*$^{-/-}$ mice (Bertrand et al., 1999; Hicks et al., 2000; Kuroda et al., 2000). FET proteins are capable of promoting invasion and pairing of a homologous ssDNA sequence with a dsDNA molecule *in vitro* (Baechtold 1999; Bertrand 1999; Guipaud 2006), which suggests a possible role for FET proteins in the D-loop formation step of homology-directed DNA double-strand break repair (HDR), while other studies showed that the FUS LCD is phosphorylated in response to DNA damage by DNA damage-activated protein kinases DNA-PKcs and ATM (Gardiner et al., 2008; Han et al., 2012)., which are important regulatos of non-homologous end joining. Consistent with a direct or indirect role for FUS in DSBR, we and others showed that shRNA-mediated depletion of FUS reduced the repair of HDR and NHEJ reporter substrates (Mastrocola et al., 2013; Rulten et al., 2014; Wang et al., 2013).

A role in the DNA damage response is further suggested by poly (ADP)-ribosyl (PAR) polymerase (PARP)-dependent localization of FUS to sites of microirradiation-induced DNA damage (Mastrocola et al., 2013; Rulten et al., 2014; Wang et al., 2013). FUS is capable of interacting directly with PAR chains through its RGG-domain (Mastrocola et al., 2013) and the FET proteins are heavily PARylated in response to genotoxic stress (Jungmichel et al., 2013). Mechanistically it was reported that FUS mediates the recruitment of histone deacetylase 1 (HDAC1), KU70, NBS1, and phosphorylated H2AX (γH2AX) and ATM at sites of DNA damage

and that this recruitment pathway as well as FUS-dependent repair was compromised by ALS/FTD-associated mutations (Wang et al., 2013). It has also been proposed that FUS organizes DSBs in a PARP-dependent manner for their subsequent repair (Singatulina et al., 2019); while Wang et al. reported that FUS recruits DNA ligase III downstream of PARP activation to repair SSBs and that ALS-associated mutations in FUS disrupt its SSB repair activity (Wang et al., 2018). Finally, it was recently reported that FUS regulates the response to transcription-associated rDNA damage via association with Topoisomerase 1 in the nucleolus (Martinez-Macias et al., 2019). Despite these studies, the molecular mechanisms linking FUS to the different repair pathways in which it has been implicated remain unclear and the extent to which FUS-dependent RNA processing may contribute to reported DDR phenotypes in FUS-deficient cells is not known.

Here, we probed FUS-dependent genome protection using trancriptomic, proteomic, and functional analysis of *FUS*$^{-/-}$ cell lines. Our findings suggest that genome protection functions of FUS are particularly important in S-phase, where it contributes to BRCA1 recruitment, replicon initiation, and replication timing. These studies provide new insights into FUS-mediated genome protection in mitotically active cells.

Results

Generation and phenotypic characterization of *FUS*$^{-/-}$ cells. To discern roles of FUS in genome protection we disrupted *FUS* gene loci in U-2 OS osteosarcoma cells using CRISPR/CAS9 followed by functional reconstitution with an untagged FUS retroviral expression (see Materials and methods). To ensure rigorous results we studied multiple *FUS*$^{-/-}$ clones and selected a reconstituted *FUS*$^{-/-}$*:FUS* line with physiologic levels of FUS expression (Fig. 1A-C). Notably, protein levels of TAF15 and EWSR1 were not upregulated in *FUS*$^{-/-}$ U-2 OS cells, diminishing concerns about functional compensation.

FUS knockdown cells displayed mild IR sensitivity and modest defects in the repair of NHEJ and HDR reporter subsrates (Mastrocola et al., 2013) while a second study reported that that FUS knockdown suppressed γH2AX and 53BP1 focus formation (Wang et al., 2013). We assessed time courses of γH2AX and 53BP1 accumulation and dissolution at IR-induced foci in *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*:FUS* U-2 OS cells exposed to 2 Gy IR. The intial recruitment of γH2AX and 53BP1 to IRIF was comparable between *FUS*$^{+/+}$ and *FUS*$^{-/-}$ cell lines; however, 53BP1 and γH2AX foci persisted longer in *FUS*$^{-/-}$ cells relative to *FUS*$^{+/+}$ cells (Sup. Fig. 1A-C). Simlar findings were made for RIF1,which functions downstream of 53BP1 to promote NHEJ (not shown). Prolonged accumulation of γH2AX and 53BP1 at IR-induced foci may reflect persistent DSBs.

In contrast to findings for 53BP1, the frequency of cells displaying IR-induced BRCA1 foci was reduced in *FUS*$^{-/-}$ cells, and this was corrected by FUS reexpression (Sup. Fig. 2 A-D). The defect in BRCA1 focus formation was specific to conditions of DNA damage since unirradiated *FUS*$^{-/-}$ cells displayed more numerous BRCA1 foci than unirradiated *FUS*$^{+/+}$ cells (Sup. Fig. 2C). Given its upstream role in DNA end resection and HDR(Chen et al., 2018a), reduced recruitment of BRCA1 may contribute to modest HDR defects seen in *FUS*$^{-/-}$ cells (Mastrocola et al., 2013). Despite the changes in 53BP1 and BRCA1 recruitment to IR-induced foci, *FUS*$^{-/-}$ cells did not exhibit significant hypersensitivity to mechanistically distinct genotoxins, including hydroxyurea (HU, replication stress), mitomycin C (MMC, DNA crosslinker), camptothecin (CPT, Top1 inhibitor), and calicheamicin γ1 (CLM, radiomimetic) (Sup. Fig. 3). These findings suggest FUS is not a core mediator of DSBR in U-2 OS cells.

***FUS*$^{-/-}$ cells exhibit defects in DNA replication**. *FUS*$^{-/-}$ U-2 OS cells exhibited reduced colony outgrowth and proliferative potential that was corrected by FUS reexpression (Fig. 1D,E). Proliferation and colony growth defects were seen across independent *FUS*$^{-/-}$ close as well as *FUS*$^{-/-}$ H460 lung adenocarcinoma cells (not shown). Following synchronous release from G_1/S phase arrest, *FUS*$^{-/-}$ cells exhibited reduced reentry and progression through S phase, which was particularly pronounced at the 6 h timepoint (Fig. 2A). The S-phase delay in *FUS*$^{-/-}$ cells was further revealed through EdU incorporation experiments. Specifically, *FUS*$^{-/-}$ cells exhibited reduce S-phase entry 6 h following release from a double thymidine block and accumulated in G_2/M to a lesser degree than *FUS*$^{+/+}$ or *FUS*$^{-/-}$*: FUS* cells 12 h following release (Fig. 2B and Sup. Fig .4). These experiments also revealed slightly reduced levels of EdU incorporation in asynchronously growing *FUS*$^{-/-}$ cells relative to *FUS*$^{+/+}$ or *FUS*$^{-/-}$*:FUS* cells (Fig. 2B).

We performed RNA-Seq to establish gene expression correlates for DNA replication defects of FUS-deficient cells. We identified ~700 genes that were differentially expressed between *FUS*$^{+/+}$ and *FUS*$^{-/-}$ cells that were corrected by FUS reexpression (Sup. Fig. 5A and B). Gene set enrichment analysis(GSEA) revealed that cell cycle, DNA repair and DNA replication processes were downregulated while immunomodulatory pathways were upregulated in in *FUS*$^{-/-}$ cells (Sup. Fig. 5C, Fig. 3A and 3D). DNA replication-associated genes that were downregulated in *FUS*$^{-/-}$ cells included *GINS4*, *MCM4*, and *RFC3*, *RCF4*, and *TIMELESS*, (Fig. 3B and C). DNA repair related genes, including *WRN*, *PRKDC*, *FANCD2*, *FANCA*, *RAD52*, were also downregulated in *FUS*$^{-/-}$ cells (Fig. 3E and F). Interestingly, the NHEJ factor *53BP1* was upregulated in *FUS*$^{-/-}$ cells (Sup. Fig. 5E). A subset of gene expression changes evident in RNA-Seq data were confirmed by qPCR (Sup. Fig. 5D and E). In sum, downregulation of S-phase genes is compatible with reduced proliferative potential of *FUS*$^{-/-}$ cells.

To ascertain impacts of FUS deficieny on replication fork (RF) dynamics, we performed DNA fiber analysis (Tonzi et al.), on *FUS*$^{-/-}$, *FUS*$^{+/+}$, *FUS*$^{-/-}$:FUS cells sequentially labeled with IdU and CldU. *FUS*$^{-/-}$ cells exhibited significant reductions in CldU track lengths indicative of reduced DNA replication rate (Fig. 4B). *FUS*$^{-/-}$ cells also showed delayed RF restart following release from a transient hydroxyurea (HU) block (Fig. 4C). Both replication velocity and replication restart phenotypes were rescued by FUS reexpression. Because a reduced rate of DNA replication can lead to micronucleus formation and genomic instability Hoffelder et al., 2004), we measured micronuclei in *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*:FUS* U-2 OS cells treated with a low dose of the DNA polymerase alpha inhibitor aphidicolin. *FUS*$^{-/-}$ cells exhibited increased rates of micronucleus formation relative to *FUS*$^{+/+}$ and *FUS*$^{-/-}$*:FUS* U-2 OS cells, suggesting that FUS enhances genome stability under replication stress (Fig. 4A).

FUS regulates pre-replication complex (pre-RC) loading and associates with DNA replication factors. Given their reduced DNA replication rate, we investigated whether *FUS*$^{-/-}$ cells exhibited defects in the chromatin loading of replication licensing factors, including the origin recognition complex (ORC), CDC6, and CDT,and the MCM replicative helicase (Fragkos et al., 2015)). Mitotically arrested *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*:FUS* cells were released into early G_1 phase and soluble and chromatin fractions analyzed by immunoblotting. FUS-deficient cells showed normal cell progression from G_2/M to G_1 phase and unchanged ORC loading onto chrmatin in G_1 (Fig. 5A and B). By contrast, recruitment of CDC6 and CDT1 was significantly decreased in *FUS*$^{-/-}$ cells and rescued by FUS reexpression (Fig. 5B). As expected, CDC6 and CDT1-dependent loading of MCM complex was also reduced in *FUS*$^{-/-}$ cells (Sup. Fig. 6). Collectively, these results revealed that FUS facilitates ORC-dependent recruitment of pre-RC factors CDC6 and CDT1 to replication origins.

Reasoning that FUS may play direct roles pre-RC loading and or DNA repair, we performed quantitative proteomic analysis of FUS complexes using a chromatin-IP procedure in which endogenous FUS-chromatin complexes were digested with nuclease prior to immunoprecipitation with α-FUS antibodies and analysis by quantitative mass spectrometry (MS) (Mohammed et al., 2016). The same chromatin-IP procedure was carried out using *FUS*$^{-/-}$ cells as a negative control. GSEA using all identified FUS interactants revealed RNA processing, DNA repair, and DNA replication as functional processes that were statistically overrepresented in the dataset of FUS-interacting proteins (Sup. Fig. 7A). The abundance of RNA-binding proteins (RBPs) in FUS complexes is consistent with other published studies (Kawaguchi et al., 2020; Sun et al., 2015). Nucleotide excision repair and DNA strand elongation proteins were among the most significantly enriched pathways within the DNA replication/repair gene sets (Sup. Fig. 7A). We plotted those proteins within DNA repair and replication GO terms that showed a nominal 1.3-fold enrichment in IPs from *FUS*$^{+/+}$ cells relative to *FUS*$^{-/-}$ cells (Fig. 6A). Proteins of interest include DSBR factors (DNA-PK, Ku70, Ku80, PNKP), SSBR/BER proteins (PARP1, FEN1,PNKP, APEX1), DNA replication factors (DNA polymerase δ, PCNA, and UHRF1), and topoisomerases (TOP1, TOP2α). The presence of SSBR/BER factors, including PARP is consistent with the ability of FUS to bind to PAR chains (Mastrocola et al., 2013) while the presence of POLδ but not POLε in FUS IPs is interesting given their participation in leading strand and lagging strand DNA synthesis, respectively (Burgers and Kunkel, 2017). We carried out validation co-IP assays to confirm that endogenous FUS interacted with TOP1, PCNA, POLδ1, and FEN1 in unsychronizyed (Fig 6B) or synchronized S phase cells (Fig 6C) and further validated association between FUS and POLδ1, PCNA, and FEN1 in proximity ligation (PLA) assays (Fig. 6D and E).

The replication defects in *FUS*$^{-/-}$ cells and interaction with DNA replication factors raised the possibility that FUS directly participates in DNA replication. To investigate this possibility, we carried out an iPOND assay that measures the association of proteins with nascently synthesized DNA (Sirbu et al., 2011). *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*:FUS* U-2 OS were pulse labeled with EdU and then chased with thymidine in the absence or presence of 2 mM HU prior to formaldehyde crosslinking and isolation of EdU-protein complexes. As expected, the abundance of the PCNA sliding clamp in EdU-labeled complexes decreased during the thymidine chase period as the replisome advanced beyond the region of nascent, EdU-labeled DNA (Fig. 3D). Although FUS was also observed in EdU-labeled DNA, its abundance was slightly increased following thymidine chase, as was histone H3 (Fig. 3D). A similar iPOND labeling pattern has been described for DNA-binding proteins such as HMGA1 and LaminB1 that maintain high-order chromatin (Lopez-Contreras et al., 2013). This result suggests that, although FUS associates wih replication factors and is proximal to replicating chromatin, it does not translocate with the active replisome.

FUS regulates DNA replication timing. Chromosomal replication is stochastically initiated from hundreds of origins that fire with characteristic, heritable timing (Fragkos et al., 2015). Replication timing (RT) can be qualitatively evaluated according to the pattern of 5-Bromo-2´-deoxyuridine(BrdU) or 5-Ethynyl-2´-deoxyuridine (EdU) incorporation following synchronized release from a double thymidine block (Dimitrova and Berezney, 2002). Early S-phase cells exhibit a uniform EdU incorporation pattern (Fig. 7A, white arrows); middle S-phase cells exhibit perinuclear and perinucleoloar EdU incorporation (Fig. 7A, yellow arrows); and late S-phase cells exhibit large punctae of EdU incorporation (Fig. 7A, green arrows). Origins with shared firing kinetics are topologically organized into chromatin subdomains in a process that requires RIF1 (Cornacchia et al., 2012; Dileep et al., 2015; Kanoh et al., 2015; Mattarocci et al., 2016;

Sima et al., 2018; Yamazaki et al., 2012); however, few other timing regulators have been identified.

We noted that the frequency of mid-S phase staining patterns was reduced ~50% in *FUS*$^{-/-}$ cells relative to *FUS*$^{+/+}$ cells (Fig. 7A, B), suggesting a potential RT defect. To rule out the apparent defect was not due to delayed S-phase entry of *FUS*$^{-/-}$ cells we carried out a timecourse analysis of *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*:FUS* cells released from thymidine block for 4, 6, or 8 h. FUS$^{-/-}$ cells exhibited reduced frequencies of the mid-S-phase staining pattern at all three timepoints, even though the frequency of late S-phase patterns more than doubled from 4-8 h (Fig. 7C and D). Importantly, FUS reexpression reversed the mid-S phase RT defect of *FUS*$^{-/-}$ cells (Fig. 7C and D). From this we conclude that FUS-deficient cells harbor RT defects that cannot be solely attributed to reduced rates of replication.

To follow up on the EdU labeling studies we measured genome-wide RT in *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*:FUS* U-2 OS cells using a Sort-Seq workflow (Koren et al., 2012). Propidium iodide-stained *FUS*$^{-/-}$, *FUS*$^{+/+}$ and *FUS*$^{-/-}$*: FUS* U-2 OS cells were sorted into G_1 and S-phase fractions prior to genomic DNA isolation and deep sequencing (see Materials and Methods). The S/G_1 phase read ratio was used to establish relative DNA copy between samples, with a higher ratio reflecting earlier RT (Fig. 8A). Using a fixed window method of read binning, we found that *FUS*$^{-/-}$ cells exhibited widespread changes in RT relative to *FUS*$^{+/+}$ and *FUS*$^{-/-}$*:FUS* cells that was consistent across two biological replicates (Fig. 8C). FUS deficiency impacted bi-directional RT switches and was highly position dependent. For example within the same 30 Mb interval of Chr18, *FUS*$^{-/-}$ cells exhibited accelerated RT (Fig. 8B, tan shading) and delayed RT (Fig. 8B, blue shading). The bi-directional RT switches in *FUS*$^{-/-}$ cells further suggests that timing changes in *FUS*$^{-/-}$ cells are not simply a byproduct of reduced RF speed.

Genome-wide bi-directional RT switches were further confirmed by RT distribution differences between *FUS*$^{+/+}$ and *FUS*$^{-/-}$ cells in both biological replicates (Fig.8D and E). Although the RT distribution of *FUS*$^{-/-}$ cells skewed slightly earlier than *FUS*$^{+/+}$ cells when examined across all chromosomes (Fig. 8F and Supp. Fig. 8A), RT directional changes were highly chromosome dependent. For example, while Chr2 did not show significant RT distribution differences between *FUS*$^{+/+}$ and *FUS*$^{-/-}$ cells, the RT distributions of Chr5 an Chr20 skewed early and late, respectively, in *FUS*$^{-/-}$ cells relative to *FUS*$^{+/+}$ cells (Fig. 8G to I and Sup. Fig. 8B to D). In summary, our data indicates FUS influences genome-wide RT in a chromosomal context-dependent manner.

Characterization of FUS-associated replication domains. The above findings indicate that FUS deficiency leads to altered timing of chromosomal regions that we refer to as FUS associated replication domains (FADs). To determine whether there are common features linking FADs we employed the unsupervised Segway deep learning tool (Chan et al., 2018; Hoffman et al., 2012) (Liu et al., 2016) to *de novo* segment replication domains (RDs) in our samples (see materials and methods). Three nonoverlapping contiguous segments were used to assign replication timing profiles into three types of RDs: early (ERD) , late (LRD) and mid (MRD), which spans the transition between early and late zone. Genomic coverage of all three types of RDs did not significantly change between *FUS*$^{-/-}$ cells relative to *FUS*$^{+/+}$ cells (Fig. 9A,B). However, the average size of LRDs was significantly decreased in *FUS*$^{-/-}$ cells (Fig. 9C).

To further characterize FADs, overlapping RDs in *FUS*$^{+/+}$ and *FUS*$^{-/-}$*:FUS* cells were intersected and then substracted from corresponding RDs in *FUS*$^{-/-}$ cells using bedtools. The resulting FADs (ERD-FUS, MRD-FUS, and LRD-FUS) comprised 11.36%, 39.73% and 21.85% of the total ERDs, MRDs, and LRDs in *FUS*$^{-/-}$ cels and represented 4.37%, 9.26% and 6.53% of whole

genome sequence, respectively (Fig.9D). In total, FADs covered ~20% of the genome in U-2 OS cells. RT signals of FADs were centered and the distribution and heatmap analysis were performed and showed they were correctly identified (Fig. 9E ans Sup. Fig. 8E to G). Consistent with earlier studies (Woodfine et al., 2004), a positive correlation between GC content and RT was found, with ERD-FUS exhibiting high GC content and LRD-FUS exhibiting low GC content (Fig. 9F). The GC content of ERD-FUS and LRD-FUS were significantly lower than the corresponding unfiltered ERD-Total, and LRD-Total. The GC contents were comparable near the center regions MRD-FUS and MRD-Total, while MRD-FUS flanking regions exhibited higher GC content (Fig. 9G to I). Finally, we next examined FADs for gene functional enrichment. Surprisingly given the non-neuronal nature of U-2 OS cells, we found LRD-FUS were highly enriched in nervous system development-related genes and, more specifically, genes encoding ion gated channels (Fig. 9J and K). These findings may be relevant to chromatin-associated functions of FUS in neurons.

FUS is enriched in detergent insoluble nuclear structures. Given its role in RT, we wished to investigate the subnuclear localization of FUS in asynchronous cells and during S phase. Following detergent preextraction, endogenous FUS formed irregular puncta in nuclear and along the nuclear envelope, while *FUS*$^{-/-}$ cells showed minimal staining with FUS antibodies (Fig. 10A). Stably expressed HA-FUS also localized to nuclear punctae (Sup. Fig. 9A). However FUS did not colocalize with with RIF1, a master regulator of RT (Sup. Fig. 9B). The latter finding suggest that FUS and RIF1 regulate RT through distinct mechanisms. FUS punctae were not diminished by RNAase treatment but were largely abolished by the RNA/DNA nuclease Benzonase (Fig. 10B). To investigate whether endogenous FUS punctae represent phase-separated liquid droplets reported in other studies time (Altmeyer et al., 2015; Chong et al., 2018; Kroschwald et al., 2015; Kroschwald et al., 2017; Li et al., 2013; Patel et al., 2015; Peskett et al., 2018), we treated U-2 OS cells with 1,6-hexanediol(1,6-HD). 1,6-HD failed to disperse FUS punctae even after long incubation periods, suggesting that these structure do not meet the operational definition of liquid droplets (Fig. 10C).

Discussion

FUS DNA repair functions have been deduced from its PARP-dependent recruitment to sites of microirradiation; its coimmunoprecipitation with repair proteins; and the modest chromosome instability and DSB repair defects of FUS-deficient cells (Deng et al., 2014; Hicks et al., 2000; Martinez-Macias et al., 2019; Mastrocola et al., 2013; Rulten et al., 2014; Singatulina et al., 2019; Wang et al., 2018; Wang et al., 2013). Despite these results, a unifying role for FUS in genome proteciotn has yet to emerge. Using *FUS*$^{-/-}$ cells with and without reconstitution we found that, while FUS plays a supporting role in DSB repair, it is prominently involved in both the initiation and timing of DNA replication. DNA replication defects plausibly contribute to genome instablity and DDR-related phenotypes ascribed to FUS-deficient cells.

FUS is among the first factors recruited to sites of microirradiation, which is driven through association of FUS RGG domains with PAR chains (Altmeyer et al., 2015; Mastrocola et al., 2013; Rulten et al., 2014; Singatulina et al., 2019; Wang et al., 2013). FUS is also reportedly required for the assembly of IR-induced 53BP1 foci (Wang et al., 2013), despite the fact that FUS does not accumulate at these structures (Mastrocola et al., 2013). Results in Sup. Fig. 1A-B clearly show that γH2AX and 53BP1 recruitment occurs independently of FUS in U-2 OS cells, with similar findings made for *FUS*$^{-/-}$ H460 cells (not shown). In fact, 53BP1 foci were significantly larger and more persistent in *FUS*$^{-/-}$ cells relative to *FUS*$^{+/+}$ controls (Sup. Fig. 1A). This result appears to be congruent with findings of Altmeyer et al. who reported that overexpression of the EWSR LCD suppressed IR-induced 53BP1 focus formation (Altmeyer et al., 2015). It is conceivable that FUS inhibits local assembly of 53BP1 complexes and/or limits their lateral spread along damaged chromatin. Non-exclusively, persistent 53BP1 foci may reflect delayed kinetics of DSB repair in *FUS*$^{-/-}$ cells. Chromatin-bound FUS notably interacted with DNA-PK and its Ku70 and Ku80 DNA-binding subunits that mediate NHEJ; however, *FUS*$^{-/-}$ U-2 OS cells were not appreciably radiosensitive, indicating FUS is not an essential NHEJ factor.

Consisent with their slow growth phenotype, *FUS*$^{-/-}$ cells exhibited reduced RF speed (Fig. 4B), delayed RF restart (Fig. 4C), reduced expression of S-phase-assoicated genes (Fig. 3C), and reduced loading of pre-RC complexes (Fig. 5B). A potentially direct role for FUS in DNA replication was suggested by the presence of DNA replication factors in FUS-chromatin complexes (Fig. 6). The association of FUS with lagging strand synthesis factors POLδ1, PCNA and FEN1, but not leading strand POLε, further suggested that FUS may play a role in the deposition or removal of RNA primers and/or the ligation of single-strand nicks on the lagging strand. It is worth noting that PARP, which was also present in FUS-chromatin complexes, contributes to the ligation of Okazaki fragments on the lagging strand (Hanzlikova et al., 2018). Despite these interactions, FUS did not stably associate with translocating replisomes in the iPOND assay (Fig. 4D). Although this does not necessarily rule out a direct role for FUS at RFs, we speculate that FUS impacts DNA replication are a reflection of its impacts on local chromatin structure and transcription.

To our knowledge, this is the first study to implicate FUS in the control of RT. The RT program is is a stable, cellular characteristic that is established in early G_1 phase(Dileep et al., 2015; Dimitrova and Berezney, 2002; Dimitrova and Gilbert, 1999). Spatiotemporal control of RT is highly dependent on the master timing factor RIF1, a chromatin-bound factor that also plays important roles in RF stablilzation and DSBR pathway choice (Escribano-Diaz et al., 2013) (Buonomo, 2017)·(Dev et al., 2018; Gupta et al., 2018; Mirman et al., 2018; Noordermeer et al., 2018). RIF1-deficient mammalian cells or yeast exhibit spatial changes in DNA replication that correlate with premature replication origin firing (Cornacchia et al., 2012; Hayano et al., 2012;

Silverman et al., 2004; Xu et al., 2010; Yamazaki et al., 2012). Recent studies have correlated genome-wide RIF1 chromatin occupancy with the RT of individual chromatin domains and established a role for RIF1 in the bundling of coregulated origins, termed RIF1-associated domains, or RADs (Foti et al., 2016). Beyond RIF1, few genetic regulators of RT have been identified(Fernandez-Vidal et al., 2014). Our findings suggest that FUS acts bidirectionally to control RT in a chromosome context-dependent manner. The fact that some chromosomal domains replicate earlier in *FUS*$^{-/-}$ cells relative to *FUS*$^{+/+}$ cells suggests that the RT functions of FUS are at least partially independent from its positive contributions to DNA replication iniitation.

The distinct colocalization patterns between RIF1 and FUS and the absence of RIF1 peptides in FUS complexes strongly suggests that FUS contributes to RT independent of RIF1. Consistent with this, while RIF1 is a well characterized suppressor of pre-RC assembly of origin firing (Alver et al., 2017), FUS enhanced pre-RC chromatin loading in early G_1-phase cells (Fig. 5 and Sup. Fig. 6) without impacting ORC binding.

FUS has gained wide notoriety for its ability to undergo reversible liquid to solid phase transitions that may be important in transcriptional activation and RNA splicing (Boeynaems et al., 2018) while PAR-dependent assembly of FUS oligomers may enhance DSBR, SSBR, or as noted above, lagging strand synthesis(Altmeyer et al., 2015; Singatulina et al., 2019). We noted that FUS formed irregular, detergent-resistant punctae that were liberated upon Benzonase treatment, suggestive of chromatin association. Analogous to what has been described for RIF1(Foti et al., 2016; Yamazaki et al., 2012), we speculate that the RT functions of FUS are linked to its ablity to oligomerize and cluster chromatin loops. Because FUS punctae were resistant to hydoxynonenal, this chromatin organizing feature may not involve liquid demixing. Alternatively the RT defects in *FUS*$^{-/-}$ cells may be an indirect consequence of transcriptional changes and/or due to changes in the splicing of genes that themselves regulate RT. In conclusion, our findings establish new roles for FUS in whole genome wide DNA replication and timing regulation that may contribute to broader genome instability deficits of FUS-deficient cells.

Materials and Methods

Cell culture and gene editing

The U-2 OS, H460 and HEK293T cell line was obtained from the American Type Culture Collection (ATCC). U-2 OS and U-2 OS derivative cell lines were grown in McCoy's medium (Corning, 10-050-CV). H460 cells were grown in RPMI-1640 medium (Corning, 10-043-CV). HEK293T cells were grown in DMEM medium (Corning, 10-013-CV). All cell lines were grown in its medium with 10% fetal bovine serum (Atlanta biologicals) and 1% Penicillin/Streptomycin (Corning, 30-002-CI) and incubated at 37°C in 5% CO_2. For G_1/S boundary via double thymidine block. Briefly, cells were treated with 2mM thymidine for 19 hours and 16 hours with a 9 hours interval of growth without thymidine. Cells were washed three times with PBS, and then released into S phase and harvested at indicated time points.

FUS$^{-/-}$ cells were generated by transient transfection of U-2 OS cells with pX459 (v2, Addgene plasmid # 62988) vectors(Ran et al., 2013) expressing sgRNAs (CGCCAGTCGAGCCATATCCC and AGAGCTCCCAATCGTCTTAC) targeting exon 4 using jetPRIME (Polyplus). Twenty-four hours after transfection, cells were selected for 72h with 1μg/ml puromycin and then cells were diluted to 96-well-plate with 1cell/well and single clones were isolated and screened for FUS knockout by Western blotting. All clones were sequenced around the targeted sequence and four clones were selected for further study. We reconstituted *FUS*$^{-/-}$ Cl.110 with a FUS CDS cloned into a pQCXIH CMV/TO DEST retroviral vector (addgene, #17394) vector by Gateway cloning. As a negative control, the GUS gene from vector pENTRGUS (invitrogen) was also cloned into pQCXIH CMV/TO DEST vector. Retroviral plasmids were packaged with GP2-293 packaging cell line (Clonetech,631458). Stably transduced cells were selected with 50μg /ml hygromycin for 1 week and single clones isolated, expanded, and tested for FUS expression.

EdU labeling, flow cytometry, microscopy, and DNA fiber analysis

For cell cycle progression experiments U-2 OS cells were incubated with 20 μM EdU for 30 min before collection and then fixed with ice-cold 70% ethanol. EdU detection was performed using the Click-IT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Life Technologies, C10634). Propidium (PI) was added to a concentration of 50 μg/ml. Flow cytometry was performed on Thermo Fisher Attune, and data was analyzed and organized using FlowJo software. For in situ EdU and BrdU staining, U-2 OS cells were pulse labelled for 30 min with 20μM BrdU or EdU and fixed with 4% paraformaldehyde (PFA). For BrdU detection, cells were then incubated with 2M HCl for 30 min and then permeabilized with 0.2% Triton-X100 for 15 min at room temperature, washed and blocked in 3% BSA. Cells were stained with BrdU primary antibody (Santa Cruz, sc-32323) in 3% BSA and incubated overnight in 4°C, followed by washing in PBST (PBS with 0.02% Tween-20) and incubation with appropriate secondary antibodies in 3% BSA for 1 h at room temperature. EdU detected by click chemistry and described above. Samples were mounted in VECTASHIELD mounting medium with DAPI (Vector, H-1200) before imaging. For general immunostaining experiments, cells were seeded into 12-well-plate with glass coverslip (and transferred to a humidity chamber for immunostaining with appropriate antibodies. Nuclear DNA either stained with 0.5μg/ml DAPI for 10 min at room temperature and then mounted with mounting medium for fluorescence (Vector, H-1000), or directly mounted in mounting medium with DAPI for fluorescence (Vector, H-1200) before imaging. Images were acquired using a Nikon A1RS Confocal Microscope under a 63x oil immersion objective. Images were organized using Fiji ImageJ software. PLA foci were counted in CellProfiler (version 3.1.5). DNA fibers were prepared and analyzed as described in (Tonzi et al.). In brief, cells were pulsed

with 50 μM IdU and CldU for times indicated in each experiment. Cells were lysed directly on glass slides, fixed, denatured, stained, and imaged with Keyence BZ-X710 microscope. Image analysis were done with ImageJ. A minimum of 150 fibers were measured for each independent experiment and analysis shows mean of three independent experiments (biological replicates).

RNA-Seq and gene expression

Total RNA was isolated using the TRIzol reagent (Invitrogen, 15596018) following the manufacturer's protocol and treated with TURBO Dnase (Invitrogen, AM2239). Then RNA samples were sent to Novogene (Novogene Co., Ltd, Sacramento, CA) for non-stranded cDNA library building and sequencing at PE150 with NovoSeq 6000. Raw reads adapters were trimmed by fastp(Chen et al., 2018b) and then were mapped to human genome(GRCh38) by STAR with the setting suggested by ENCODE project (https://github.com/ENCODE-DCC/rna-seq-pipeline). The number of RNA-Seq reads mapped to each transcript were summarized with featureCounts(Liao et al., 2014) and differential expression was called using DESeq2(Love et al., 2014). Three biological replicates were used for each sample. For qPCR analysis total RNA was reverse transcribed into cDNA using SuperScript IV VILO Master Mix with ezDnase enzyme Kit (Invitrogen, 11766050). The primers were designed by Beacon Designer or NCBI primer-blast online tool. q-PCR reaction was performed on Bio-Rad CFX RealTime PCR system using iTaq Universal SYBR Green Supermix (Bio-Rad, 1725125)

Replication timing analysis.

Cells were prepared and collected accordingly to (Koren et al., 2012) with the following modifications. Around 10 million asynchronous cells were collected and fixed in 70% ethanol. Fixed cells were washed with ice-cold PBS and treated with Accutase (CORNING, 25-058-CI) for 20 minutes at room temperature. Cells were pelleted and resuspended in 2 ml PBS with 250 μl 10 mg/ml RNaseA and incubated at 37°C for 30 minutes and stained with propidium iodide (PI), and then sorted to G_1 and S-phase fractions by flow cytometry. DNA extracts from sorted cells were prepared using with DNeasy Blood and Tissue Kit (Qiagen, 69504) and single-end 100-base sequencing libraries prepared using TruSeq kit (Illumina) and deep sequencing was performed on HighSeq 2500. The analysis was carried out according to Marchal et al. (Marchal et al., 2018). Briefly, Reads were trimmed by fastp and then were mapped onto the human genome (GRCh38) using bowtie2. The replication timing (RT, S/G_1 ratio) was calculated in a fixed window size of 2Kb. Then RT raw data were used for quantile normalization, and then smoothened with Loess smoothing. Two biological replicates were analyzed separately.

Immunoblotting

For whole-cell extraction, cells were resuspended in high salt lysis buffer (50 mM Tris, pH 7.5, 300 mM NaCl, 10% glycerol, 0.5% Triton X-100, 2mM $MgCl_2$, 3mM EDTA, 1% Protease Inhibitor Cocktail (Sigma, P8340-5ml)) supplemented with Benzonase (50 U/ml) and incubated on ice for 20 min followed by the addition of 4X SDS-loading buffer and heating at 95°C for 15 min. For chromatin fractionation, cells were resuspended in cytoskeleton (CSK) buffer (20 mM HEPES-KOH (pH 7.4), 100 mM NaCl, 3 mM $MgCl_2$, 300 mM sucrose and 1% Protease Inhibitor Cocktail(Sigma, P8340-5ml)) containing 0.5% Triton X-100, incubated on ice for 20 min, and centrifuged for 5min at 5,000 x g at 4 ^{o}C. The supernatant was transferred to a new tube and saved as soluble fraction (SF), while the pellet/chromatin fraction, (CF) was washed twice in CSK buffer without detergent and resuspended in CSK buffer with Benzonase (50U/ml) for 20 min digestion at which time 4 X SDS loading buffer was added and the lysates heated to 95°C for 15 min. For immunoblotting, samples were separated by SDS-PAGE and transferred to PVDF membranes and immunoblotted with primary antibodies and LI-COR IRDye secondary antibodies (IRDye 800CW goat anti-rabbit and IRDye 680RD goat anti-mouse) as described

(Kim et al., 2018; Kim et al., 2016). Signals were acquired using Odyssey bio-systems (LI-COR Biosciences). Immunoblotting results were analyzed and organized with ImageStudio Lite software (LI-COR).

FUS purification and mass spectrometry

RIME (rapid immunoprecipitation mass spectrometry of endogenous proteins) assay of FUS were carried out as described (Mohammed et al., 2016) with the following modifications. Briefly, around 20 million cells were counted and fixed with 20 ml 1% formaldehyde solution for 8 minutes at room temperature. Fixation was quenched by adding 0.12M Glycine. The soluble fraction was extracted in 10ml of LB1 (50 mM HEPES-KOH (pH 7.5), 140 mM NaCl, 1 mM EDTA, 10% Glycerol, 0.5% NP-40, 0.25% Triton X-100, 1% Protease Inhibitor Cocktail (Sigma, P8340-5ml)) for 10 min with rotation at 4°C. Cell nuclei were pelleted and washed once with 10ml LB2 (10 mM Tris-HCl(pH 8.0), 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Protease Inhibitor Cocktail) and then resuspended in 500 µl LB3 (10 mM Tris-HCl (pH 8.0), 100 mM NaCl, 2.5 mM $MgCl_2$, 0.1% (W/V) sodium deoxycholate, 0.5% Triton X-100, 1% Protease Inhibitor Cocktail) with 500 U Benzonase and incubated at room temperature for 30 min. Benzonase was deactivated with 2 mM EDTA, 1 mM EGTA. To this mixture was added 50 µl 10% Triton X-100, 37.5 µl of 4 M NaCl, and LB3 to bring the total lysate volume of each sample to 1 ml. Digested lysates were briefly sonicated using a 10s/50s on/off cycle for three times at 40% power and clarified by centrifugation at 20,000g for 10 min at 4°C and supernatants were incubated with 10 µg FUS antibody (Bethyl, A300-302A) overnight at 4°C with rotation. Subsequently, 50 µl of pre-washed Dynabeads protein G (Invitrogen, 10003D) was added to the lysates and incubated for additional 4 h at 4°C. For western blot, beads were washed sequentially with 1 ml LB3 and 1 ml RIPA buffer (50 mM HEPES-KOH (pH 7.5), 0.5 M LiCl, 1 mM EDTA, 1% NP-40, 0.7% (W/V) sodium deoxycholate, 1% Protease Inhibitor Cocktail) once and boiled in 100µl 2 x SDS buffer. For mass spectrometry, beads were washed 5 times with 1 ml RIPA buffer and twice in 1 ml of cold fresh prepared 100 mM ammonium hydrogen carbonate (AMBIC) solution and processed as described (Mohammed et al., 2016).

FUS RIME IPs from *FUS*$^{+/+}$ and *FUS*$^{-/-}$ cells were subjected to tryptic digestion and orbitrap mass spectrometry (MS) using the filter aided sample preparation (FASP) method (Wisniewski et al., 2009). We performed two technical replicates for each of the three biological replicates. The software, MetaMorpheus, was employed to do identification of peptides and proteins, and quantification(Shortreed et al., 2015).

Cell proliferation, survival, and iPOND assays

For cell proliferation assay, 500 cells were plated in each well of 96-well-plate and each sample had 6 replicates and monitored for 6 days from day 0 to day 5 by CellTiter-Glo 2.0 Assay (Promega, G9242) according to the manufacturer's instructions. The luminescence was recorded by SpectraMax i3 (Molecular Devices). For cell viability assay, 1000 cells/well were plated in 96-well-plate with drug-free medium and varying amounts of drugs were added after 12 h in fresh medium. Cell survival was assayed as same as cell proliferation assay after 3 or 5 days as indicated in figure legend. Data was analyzed and organized by Prism 7.

iPOND assay

The iPOND experiments were performed as described in (Dungrawala and Cortez, 2015; Tonzi et al.) with minor modifications. Briefly, ~10^8 cells were pulse-labelled with 20 µM EdU for 15 min followed by a 1 h chase with 20 µM thymidine. To induce replication stress, cells were treated with 2 mM Hydroxyurea (HU) after EdU labeling for 2 h, and then chased with 20 µM thymidine for 1 h. Each plate was crosslinked with 10 ml 1% formaldehyde in PBS for 20 min

and quenched by adding 1ml of 1.25 M glycine for 5 min. The conjugation of biotin to EdU was carried out by click chemistry reaction for 2 hours at room temperature in click reaction buffer(10 μM biotin-azide, 10mM sodium-L-ascorbate, 2mM CuSO4 and 800μM THPTA in PBS) and followed by washing once in 0.5% BSA in PBS and once in PBS. Cells were resuspended in LB3 with 500U Benzonase (Santa Cruz, sc-202391) and incubated at room temperature for 30 minutes. Digested lysates were briefly sonicated using a 10s/50s on/off cycle for four times at 40% power and clarified by centrifugation at 8,000g for 10min at 4°C and supernatants were incubated overnight with 50μl magnetic streptavidin beads (Dynabeads MyOne Streptavidin T1, 65601) at 4°C with rotating. Beads were washed once in 1ml washing buffer (20mM Tris-HCl(pH 8.0), 500mM NaCl, 2mM EDTA, 0.1%(W/V) sodium deoxycholate,1% Triton X-100), once with 1ml RIPA buffer(50mM HEPES-KOH(pH 7.5), 0.5M LiCl, 1mM EDTA, 1% NP-40, 0.7%(W/V) sodium deoxycholate, 1% Protease Inhibitor Cocktail) and twice in LB3 buffer, and then proteins were eluted by boiling in 2 x SDS buffer for 25 min.

Statistical processing

Statistical analysis information including individual replicates and biological replicates number, mean or median, and error bars are explained in the figure legends. The statistical tests and resulting *P* values are showed in the figure legends and/or figure panels.

Key resources table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal anti-FUS	Santa Cruz Biotechnology	sc-47711
Rabbit polyclonal anti-FUS	Bethyl	A300-302A
Rabbit polyclonal anti-EWSR1	Bethyl	A300-417A
Rabbit polyclonal anti-TAF15	Bethyl	A300-308A
Mouse monoclonal anti-MCM2	Santa Cruz Biotechnology	sc-373702
Mouse monoclonal anti-MCM4	Santa Cruz Biotechnology	sc-28317
Mouse monoclonal anti-CDC6	Santa Cruz Biotechnology	sc-9964
Mouse monoclonal anti-FEN1	Santa Cruz Biotechnology	sc-28355
Mouse monoclonal anti-POLD1	Santa Cruz Biotechnology	sc-17776
Mouse monoclonal anti-PCNA	Santa Cruz Biotechnology	sc-56
Mouse monoclonal anti-BrdU	Santa Cruz Biotechnology	sc-32323
Mouse monoclonal anti-BRCA1	Santa Cruz Biotechnology	sc-6954
Rabbit polyclonal anti-CyclinA	Santa Cruz Biotechnology	sc-751
Mouse monoclonal anti-ORC4	Santa Cruz Biotechnology	sc-136331
Goat polyclonal anti-KU70	Santa Cruz Biotechnology	sc-1487
Mouse monoclonal anti-UHRF1	Santa Cruz Biotechnology	sc-373750
Mouse monoclonal anti-TOP2A	Santa Cruz Biotechnology	sc-56803
Mouse monoclonal anti-TOP1	BD Pharmingen	556597
Rabbit polyclonal anti-CDT1	Cell Signaling Technology	8064S
Rabbit polyclonal anti-RIF1	Bethyl	A300-569A
Rabbit monoclonal anti-HA	Cell Signaling Technology	3724S

Mouse monoclonal anti-β-Tubulin	Millipore	05-661
Rabbit polyclonal anti-53BP1	Bethyl	A300-272A
Rabbit polyclonal anti-γH2AX	Cell Signaling Technology	2577S
Mouse monoclonal anti-γH2AX	Millipore	05-636
Rabbit polyclonal anti-Lamin B1	Abcam	ab16048
Normal rabbit IgG	Cell Signaling Technology	2729S
Chemicals		
Hydroxyurea	Santa Cruz Biotechnology	sc-29061
Camptothecin	Sigma	C9911
Aphidicolin	Sigma	A0781
Calicheamicin γ1	Pfizer Compound Transfer Program	
Mitomycin C	Santa Cruz Biotechnology	sc-3514
Thymidine	ACROS ORGANICS	226740050
Propidium iodide	Sigma	P4170-100mg
Paraformaldehyde	Santa Cruz Biotechnology	sc-253236A
THPTA	Click Chemistry Tools	1010-100
1,6-hexanediol	Aldrich	240117-50G
Primers		
GAPDH-F	AATCCCATCACCATCTTCCA	q-PCR
GAPDH-R	TGGACTCCACGACGTACTCA	q-PCR
β-ACTIN-F	TCCCTGGAGAAGAGCTACG	q-PCR
β-ACTIN-R	GTAGTTTCGTGGATGCCACA	q-PCR
GINS4-F	AAACAGGGTGAGGTCCAG	q-PCR
GINS4-R	CGTAGAGCCGTCATTCAAT	q-PCR
MCM4-F	GGCTAGAGTACACTGGTA	q-PCR
MCM4-R	TGTAATCTCAGCACTTCC	q-PCR
ORC3-F	GCTCGCCACTAACCTCTG	q-PCR
ORC3-R	TCTTACTGACTCTGCGTATTCCA	q-PCR
RFC4-F	CCGTTATTCTCAGATTAGGT	q-PCR
RFC4-R	GTACTTCACCCAGTTAGC	q-PCR
TIMELESS-F	CCTGTTGTCCTAGCACTT	q-PCR
TIMELESS-R	GGGATTTCGCCATATTGTC	q-PCR
53BP1-F	GTGTCTTCCTGCCTCTGA	q-PCR
53BP1-R	TGCCAAGTGGACAACAGTA	q-PCR
FANCA-F	CAGTCTCAGCCTTGTGTT	q-PCR
FANCA-R	ACCTTCTTATCTGCCTCTG	q-PCR
FANCD2-F	GCAGATGAGAGTGAGGATGAC	q-PCR
FANCD2-R	TGCTCCACCAACTTAGAACAAT	q-PCR
Software and Algorithms		
R	N/A	https://www.r-project.org/
Fiji	(Schindelin et al., 2012)	https://imagej.net/Fiji
CellProfiler	(McQuin et al., 2018)	https://cellprofiler.org/
Bowtie2	(Langmead and Salzberg, 2012)	http://bowtie-bio.sourceforge.net/bowtie2/index.shtml
Deeptools	(Ramirez et al., 2016)	https://deeptools.readthedocs.io/en/develop/
Segway	(Hoffman et al., 2012)	https://segway.hoffmanlab.org/
STAR	(Dobin et al., 2013)	https://github.com/alexdobin/STAR
FeatureCount	(Liao et al., 2014)	http://subread.sourceforge.net/
DEseq2	(Love et al., 2014)	https://bioconductor.org/packages/release/bioc/html/DESeq2.html
fgsea	(Sergushichev, 2016)	https://bioconductor.org/packages/release/bioc/html/fgsea.html
clusterprofiler	(Yu et al., 2012)	https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html
Tidyverse	N/A	https://www.tidyverse.org/
pheatmap	N/A	https://github.com/raivokolde/pheatmap
ggpubr	N/A	https://github.com/kassambara/ggpubr

Data availability

All the source data represented in the figures and bioinformatic analysis scripts are available on github (https://github.com/biofisherman/FusReplication). The accession number of Replication timing sequencing data in NCBI : PRJNA615974. The GEO number of RNA-Seq data : GSE147784.

Acknowlegments
We gratefully thank Ammon Koren provided protocol for replication timing sample preparation and communication of replication timing analysis. We are grateful to Markku Varjosalo for pcDNA5/FRT/TO/StrepIII/HA/GW vector, Pfizer Compound Transfer Program for Calicheamicin A. We thank Lance A Rodenkirch in optical imaging core and Flow Cytometry Laboratory for assistance.

Funding
National Cancer Institute [R01CA180765-01 to R.S.T.]; National Institute for Neurological Disorders and Stroke [1R21NS090313-01A1 to R.S.T.], National Institute of Environmental Health Sciences [R01ES025166 to T. T. H.]; University of Wisconsin Carbone Cancer Center Support Grant [P30 CA014520], NIH Shared Instrumentation Grants [1S10RR025483-01].

Figure legends

Figure 1. FUS promotes cell proliferation.
A, Schematic of the FUS gene targeting. Two guide RNAs, sgRNA1 and sgRNA2, were used to target FUS exon 4 (See methods). The primers, e4-Fwd and e4-Rev, were used for genotyping. B, Expression of FET proteins (FUS, EWSR1, and TAF15) in *FUS*$^{-/-}$ clones. Note lack of compensation by EWSR1 and TAF15. C, Reconstiution of *FUS*$^{-/-}$ (Cl.110) with an untagged FUS retroviral vector. The same vector expressing β-Glucuronidase was introduced as a negative control into *FUS*$^{-/-}$ cells. D, *FUS*$^{-/-}$ cell colonies exhibited reduced growth relative to *FUS*$^{+/+}$ and *FUS*$^{-/-}$:*FUS* cells. E, Cell proliferation rates of *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*: FUS* U-2 OS cells. Each sample contains 6 technical replicates. The bars represent mean ± SD. The*T* test was performed and the *P* values were shown on plot.

Figure 2. FUS is required for S-phase progression.
A, DNA replication progression was analyzed by PI staining and flow cytometry. Cells were synchronized to G_1/S boundary by double thymidine block and released into fresh growth medium for the indicated times, and stained with PI for cell cycle analysis. B, DNA progression was monitored by EdU incorporation under the same conditions as in (A). additional timepoints are presented in Sup. Fig. 4.

Figure 3. Reduced expression of replication-associated genes in FUS deficient cells.
A, Enrichment plot of DNA replication pathway from GSEA analysis using GO gene sets (biological process) in the Sup. Tab. 3. B, Heatmap of differentially expressed DNA replication genes. Genes were clustered to three groups based on ward.D2 method. C, Normalized RNA-Seq counts of cluster 2 genes involved in the DNA replication pathway. D, Enrichment plot of DNA repair pathway from GSEA analysis using GO gene sets (biological process) in the in the Sup. Tab. 3. E. Heatmap of the leading gene list of DNA repair pathway shown significate changing in all samples. Genes were clustered into two groups based on ward.D2 method. F, DNA repair related gene expressions of cluster 1 were shown in normalized counts from RNA sequencing results.

Figure 4. FUS deficiency leads to genomic instability and replication stress.
A, *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*: FUS* U-2 OS cells were treated with or without 0.2 μM aphidicolin (Aph) for 24 hours, fixed and stained with DAPI for micronucleus counting. *P* values were calculated by two-way ANNOVA test. Data are means ± SE(n=3 biological replicates). More than 250 cells for each sample in each biological replicates were counted. B, Replication fork speed is reduced in *FUS*$^{-/-}$ cells. The second pulse (CIdU) was used for measurement of track length, which was converted to micrometers using a 1 μm =2.59 kb conversion factor. The average fork length was divided by 20 min to derive replication speed. C, Replication fork restart was measured as shown in the schematic. Percentages of fork restart (% stalled forks) in HU-treated cells are shown. Data are mean± s.d.(n=3). *P* values were calculated using a t-test with Welch's correction. n.s. = no significance, * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$. D, FUS does not translocate with the replisome. An iPOND assay was performed as shown in the schematic. HEK 293T cells were pulse labeled with 20 μM EdU for 15 min and then chased with 20 μM thymidine for 1 h. For replication stress, cells were treated with 2 mM HU after EdU labeling, and then chased with thymidine for another 1 hour. Western blotting was used to assess FUS, PCNA, and histone H3 enrichment at EdU-labeled replication forks.

Figure 5. FUS regulates pre-replication complex(pre-RC) loading onto chromatin. A, Cell cycle profiles of *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*: FUS* U-2 OS cells that were synchronized in early M

phase with nocodazole and then harvested or released into G_1 phase for 5 h. B, Chromatin loading of ORC and pre-RC proteins in *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*: FUS* U-2 OS cells. Mitotic and G1 fractions were immunoblotted with the indicated antibodies.

Figure 6. FUS interacts with DNA repair and DNA replication factors.
A, FUS interacting proteins were identified by cross-linking chromatin immunoprecipitation (IP) and analyzed by MS. The results are combination of three biological replicates quantified by non-isotopic spectral peptide counting. The data shown are DNA repair (red colored) and DNA replication (blue colored) pathway related interactions based on GSEA (full listed shown in Sup. Fig. 7A). The unique peptides are summarized from three replicates raw data. The grey doted lines are 1.3 of fold change and 0.05 of *P* value. B, Coimmunoprecipitation of FUS with POLD1, UHRF1, TOP1 and PCNA in unsynchronized cells. C, Coimmunoprecipitation of FUS with FEN1 and PCNA in synchronized S phase cells. D, In situ proximity ligation (PLA) assay was employed to verify the interactions between FUS, and POLD1, PCNA and FEN1. Nuclear regions were cycled by dashed lines in PLA red channel based on DAPI signal. E, Quantification results of PLA signal in (D). The values are median of PLA foci in each sample. *P* values were calculated by Wilcox test method.

Figure 7. FUS regulates DNA replication timing (RT).
A, Asynchronous U-2 OS cells and three *FUS*$^{-/-}$ clones (Cl. 46, Cl. 65 and Cl. 110) were pulse-labeled with EdU for 20 min and scored for the presence of early, mid, or late EdU staining patterns. B, Quantification analysis of cell numbers of each S phase patterns in (A), and the percentage were calculated in each sample. C, Cells were synchronized with double thymidine and then released into S phase for indicated times.Cells were then pulse-labeled with BrdU, stained and imaged by confocal microscopy. D, Quantification results of samples using a minimum 100 cells per sample (C).

Figure 8. FUS influences genome wide RT. A, Whole genome wide replication timing profile of U-2 OS cells. The replication timing (RT) was calculated based on copy number variations between S and G_1-phase cells (S/G_1 ratio). The signal was normalized by Z-score and smoothed by Loess smoothing. B, Representative RT profiles of *FUS*$^{+/+}$, *FUS*$^{-/-}$ and *FUS:FUS*$^{-/-}$ cells across two biological replicates. Regions of RT switching between *FUS*$^{+/+}$ and *FUS*$^{-/-}$ are highlighted. C, Correlation of RT between two biological replicates by Pearson's method. The smoothed RT values were used for the correlation matrix. D, Genome-wide distribution of RT scores when comparing *FUS*$^{+/+}$ to *FUS*$^{-/-}$ or *FUS*$^{+/+}$ vs *FUS:FUS*$^{-/-}$ in two biological replicates. The bin sizes are 50 and 100 for Replicate1 (Rep.1) and Replicate2 (Rep.2) respectively. F to I, The RT density distribution for Rep. 2 was analyzed across all chromosomes (F), Chr.2 (G), Chr.5 (H) and Chr.20 (I). The RT density distribution for Rep. 1 are |shown in Sup. Fig. 8A to D. The dashed lines are the median of each sample. The Loess smoothed data was used for analysis.

Figure 9. Characterization of FUS associated domains (FADs).
A, RT profiles were segmented into three states by non-supervised package Segway as Early replication domain (ERD), Middle replication domain (MRD) and Late replication domain (LRD). The domain numbers in each sample were plotted and labeled. The two biological replicates were merged for replication domain segmentation. B, Percentages of genome coverage of replication domains in each sample were calculated based on the segmentation. The values are percentages of each domain. C, The same RT domain sizes are compared among all the samples. The Student *T*-test was used for determination of significance. D, Doughnut Pie chart of FAD coverage. The percentage of each RD (ERD, MRD, LRD; center pie) that is altered by FUS deficiency (FAD) is shown in the outside layer and the total percentage of each FAD (FAD-

E, FAD-M, FAD-L) calculated and shown in parentheses. The percentage was caculated based on the genome coverage. E, RT signal enrichment analysis of FADs in the samples.. The average domain size is ~10^6 bp (C) and ~0.5 x 10^6 bp flanking the midpoint was used for signal enrichment. Heatmap results of RT signal enrichment of changing ERD(F), MRD(G) and LRD(H) in all individual samples was shown in Sup. Fig .8E to G. F, GC content distribution in the centred FADs. GC ratio was caculated in 20Kb window. G to I, the GC content distribution in FADs compared with respective RDs ideatified in U-2 OS cells. J, Gene ontology (GO) enrichment in biological function level of FADs. The FADs were extended 3000 bases in both ends and then the gene list under the extended FADs were extracted and was used for GO analysis. K, GO analysis in molecular function level of extended FADs.

Figure 10. RNA-binding independent association of FUS with chromatin.
A, *FUS*$^{+/+}$ and *FUS*$^{-/-}$ cells were pre-extracted with CSK buffer, fixed, and stained with α-FUS. B, U-2 OS cells were pre-extracted in CSK buffer containing 0.3mg/ml Rnase A or 100U/ml Benzonase and stained with α-FUS. C, U-2 OS Cells were treated with 3% 1,6-HD for indicated times and then processed for immunofluorescence staining with FUS antibodies.

Supplemental Figures

Supplemental Figure 1. **Increased persistence of 53BP1 and γH2AX foci in irradiated *FUS*$^{-/-}$ U-2 OS cells**. A, Representative 53BP1 and γH2AX staining patterns of *FUS*$^{+/+}$ cells and two *FUS*$^{-/-}$, clones (Cl.46 and Cl.110), harvested at different times after exposure to 2 Gy IR. . *B* and *C*, Quantification of 53BP1 (B) and γH2AX (C) foci. At least 50 cells were analyzed for each sample. The bars represent mean with *SEM*. Significance was calculated using one-way ANOVA(****P<0.0001) followed by Bonferroni's Multiple Comparison Test.

Supplemental Figure 2. **FUS promotes BRCA1 recruitment to DNA damage sites**. A, *FUS*$^{+/+}$ and *FUS*$^{-/-}$ U-2 OS cells were harvested prior to or 15 min after exposure to 2 Gy IR and stained with BRCA1 antibodies. B, Cells displaying five or more BRCA1 foci were tabulated and subjected to statistical treatment using student *T-test* (n=5 five random regions). C, FUS reexpression reverses the BRCA1 focus formation defect *FUS*$^{-/-}$ cells in of S/G_2-phase. Cells were fixed and stained with BRCA1 and Cyclin A2 antibodies before or 15 min after exposure to 2 Gy IR. D, Numbers of BRCA1 foci in cyclin A-positive cells were tabulated. Student *t-test*, n=10 (random rigions).

Supplemental Figure 3. **Sensitivity of *FUS*$^{-/-}$ cells to genotoxins**. A to D, CellTiter-Glo assay was perfomed to measure the cell survival after 5-days continuous treatment with HU, CPT, MMC or CLM at the indicated concentration. 1000 cells were plated in each well. HU and MMC treatments employed three biological replicates of5 technical replicates each. CPT and CLM employed one biological replicate with 5 technical replicates. The bars represent mean ± SD. *P* values were calculated suing *t*-test. The blue *p*-values compare *FUS*$^{+/+}$*:Vec* and *FUS*$^{-/-}$*:Vec* and the green p-values compare *FUS*$^{-/-}$*:FUS* to *FUS*$^{-/-}$*:Vec*.

Supplemental Figure 4. Full time course analysis of cell cycle progression in *FUS*$^{+/+}$, *FUS*$^{-/-}$, and *FUS*$^{-/-}$*:FUS* cells shown in Fig. 2B.

Supplemental Figure 5. **RNA-Seq and GSEA results**. A, Venn diagram of differentially expressed genes (DEGs) from comparisons among *FUS*$^{-/-}$*:Vec*(wild type, WT), *FUS*$^{-/-}$*:Vec* (knockout, KO), and *FUS*$^{-/-}$*:FUS* (reconstituted, RE). B, Heatmap of genes whose altered expression in *FUS*$^{-/-}$*:Vec* cells was rescued in *FUS*$^{-/-}$*:FUS* cells. C, GSEA results in biological

processes. The GO terms shown are with adjust *p*-value of 0.01. D and E are qPCR verification results of DNA repair and replication related genes. The *β-ACTIN* and *GAPDH* genes were used as internal control normalization.

Supplemental Figure 6. FUS regulates MCM helicase complex loading onto chromatin in G_1 phase. Samples were prepared as shown in Fig. 5B.

Supplemental Figure 7. Gene set enrichment analysis of FUS interactions. A, Biological process ontology enrichment results. The enrichment were performed with R package fgsea and all pathways were shown with an adjust *p*-value lower than 0.01. DNA repair and DNA replication related enrichment pathways were shown in B and C separately.

Supplemental Figure 8. RT analysis results. A to D, the RT density distribution analysis in All chromosome(A), Chr.2(B), Chr.5(C), and Chr. 20(D) respectively in replicate 1. E to G, Heatmap results of RT signal enrichment of FAD related ERD(E), MRD(F) and LRD(G) in all individual samples.

Supplemental Figure 9. Puncta of HA-FUS in U-2 OS cells. A, Empty vector and HA-FUS plasmid were stable expressed in U-2 OS cells. Immunofluorescence imaging was preformed using α-HA HA as described in Fig. 10A. Bar size is 10 μm. B, Immunofluorescence imaging of FUS and RIF1 in cells was prepared as in A. Bar size is 10 μm.

Additional files

Table 1. list of FUS interactions ideatified by MS/MS.
Table 2. list of FUS intereactions involved in DNA replication and repair.
Table 3. list of differentially expressed genes of FUS WT vs KO.
Table 4. list of significate expression changed genes in *FUS*$^{-/-}$*:Vec* and rescued in *FUS*$^{-/-}$*:FUS*.
Table 5. list of normalized counts of RNA-Seq by DESeq2

References

Altmeyer, M., Neelsen, K.J., Teloni, F., Pozdnyakova, I., Pellegrino, S., Grøfte, M., Rask, M.-B.D., Streicher, W., Jungmichel, S., Nielsen, M.L., *et al.* (2015). Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose). Nature Communications *6*, 8088.

Alver, R.C., Chadha, G.S., Gillespie, P.J., and Blow, J.J. (2017). Reversal of DDK-Mediated MCM Phosphorylation by Rif1-PP1 Regulates Replication Initiation and Replisome Stability Independently of ATR/Chk1. Cell Rep *18*, 2508-2520.

Bertrand, P., Akhmedov, A.T., Delacote, F., Durrbach, A., and Lopez, B.S. (1999). Human POMp75 is identified as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation. Oncogene *18*, 4515-4521.

Boeynaems, S., Alberti, S., Fawzi, N.L., Mittag, T., Polymenidou, M., Rousseau, F., Schymkowitz, J., Shorter, J., Wolozin, B., Van Den Bosch, L., *et al.* (2018). Protein Phase Separation: A New Phase in Cell Biology. Trends Cell Biol *28*, 420-435.

Buonomo, S.B.C. (2017). Rif1-Dependent Regulation of Genome Replication in Mammals. Adv Exp Med Biol *1042*, 259-272.

Burgers, P.M.J., and Kunkel, T.A. (2017). Eukaryotic DNA Replication Fork. Annu Rev Biochem *86*, 417-438.

Chan, R.C.W., Libbrecht, M.W., Roberts, E.G., Bilmes, J.A., Noble, W.S., and Hoffman, M.M. (2018). Segway 2.0: Gaussian mixture models and minibatch training. Bioinformatics *34*, 669-671.

Chen, C.C., Feng, W., Lim, P.X., Kass, E.M., and Jasin, M. (2018a). Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. Annu Rev Cancer Biol *2*, 313-336.

Chen, S., Zhou, Y., Chen, Y., and Gu, J. (2018b). fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics *34*, i884-i890.

Chong, S., Dugast-Darzacq, C., Liu, Z., Dong, P., Dailey, G.M., Cattoglio, C., Heckert, A., Banala, S., Lavis, L., Darzacq, X., *et al.* (2018). Imaging dynamic and selective low-complexity domain interactions that control gene transcription. Science *361*.

Cornacchia, D., Dileep, V., Quivy, J.P., Foti, R., Tili, F., Santarella-Mellwig, R., Antony, C., Almouzni, G., Gilbert, D.M., and Buonomo, S.B. (2012). Mouse Rif1 is a key regulator of the replication-timing programme in mammalian cells. EMBO J *31*, 3678-3690.

Corrado, L., Del Bo, R., Castellotti, B., Ratti, A., Cereda, C., Penco, S., Soraru, G., Carlomagno, Y., Ghezzi, S., Pensato, V., *et al.* (2010). Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. J Med Genet *47*, 190-194.

Crozat, A., Aman, P., Mandahl, N., and Ron, D. (1993). Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature *363*, 640-644.

Deng, Q., Holler, C.J., Taylor, G., Hudson, K.F., Watkins, W., Gearing, M., Ito, D., Murray, M.E., Dickson, D.W., Seyfried, N.T., *et al.* (2014). FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. J Neurosci *34*, 7802-7813.

Dev, H., Chiang, T.W., Lescale, C., de Krijger, I., Martin, A.G., Pilger, D., Coates, J., Sczaniecka-Clift, M., Wei, W., Ostermaier, M., *et al.* (2018). Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nat Cell Biol *20*, 954-965.

Dileep, V., Ay, F., Sima, J., Vera, D.L., Noble, W.S., and Gilbert, D.M. (2015). Topologically associating domains and their long-range contacts are established during early G1 coincident with the establishment of the replication-timing program. Genome Res *25*, 1104-1113.

Dimitrova, D.S., and Berezney, R. (2002). The spatio-temporal organization of DNA replication sites is identical in primary, immortalized and transformed mammalian cells. J Cell Sci *115*, 4037-4051.
Dimitrova, D.S., and Gilbert, D.M. (1999). The spatial position and replication timing of chromosomal domains are both established in early G1 phase. Mol Cell *4*, 983-993.
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics *29*, 15-21.
Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., Than, M.E., Mackenzie, I.R., Capell, A., Schmid, B., *et al.* (2010). ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J *29*, 2841-2857.
Dungrawala, H., and Cortez, D. (2015). Purification of proteins on newly synthesized DNA using iPOND. Methods Mol Biol *1228*, 123-131.
Escribano-Diaz, C., Orthwein, A., Fradet-Turcotte, A., Xing, M., Young, J.T., Tkac, J., Cook, M.A., Rosebrock, A.P., Munro, M., Canny, M.D., *et al.* (2013). A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell *49*, 872-883.
Fernandez-Vidal, A., Guitton-Sert, L., Cadoret, J.C., Drac, M., Schwob, E., Baldacci, G., Cazaux, C., and Hoffmann, J.S. (2014). A role for DNA polymerase theta in the timing of DNA replication. Nat Commun *5*, 4285.
Foti, R., Gnan, S., Cornacchia, D., Dileep, V., Bulut-Karslioglu, A., Diehl, S., Buness, A., Klein, F.A., Huber, W., Johnstone, E., *et al.* (2016). Nuclear Architecture Organized by Rif1 Underpins the Replication-Timing Program. Mol Cell *61*, 260-273.
Fragkos, M., Ganier, O., Coulombe, P., and Mechali, M. (2015). DNA replication origin activation in space and time. Nat Rev Mol Cell Biol *16*, 360-374.
Gardiner, M., Toth, R., Vandermoere, F., Morrice, N.A., and Rouse, J. (2008). Identification and characterization of FUS/TLS as a new target of ATM. Biochem J *415*, 297-307.
Gupta, R., Somyajit, K., Narita, T., Maskey, E., Stanlie, A., Kremer, M., Typas, D., Lammers, M., Mailand, N., Nussenzweig, A., *et al.* (2018). DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity. Cell *173*, 972-988 e923.
Han, T.W., Kato, M., Xie, S., Wu, L.C., Mirzaei, H., Pei, J., Chen, M., Xie, Y., Allen, J., Xiao, G., *et al.* (2012). Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell *149*, 768-779.
Hanzlikova, H., Kalasova, I., Demin, A.A., Pennicott, L.E., Cihlarova, Z., and Caldecott, K.W. (2018). The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication. Mol Cell *71*, 319-331 e313.
Hayano, M., Kanoh, Y., Matsumoto, S., Renard-Guillet, C., Shirahige, K., and Masai, H. (2012). Rif1 is a global regulator of timing of replication origin firing in fission yeast. Genes Dev *26*, 137-150.
Hicks, G.G., Singh, N., Nashabi, A., Mai, S., Bozek, G., Klewes, L., Arapovic, D., White, E.K., Koury, M.J., Oltz, E.M., *et al.* (2000). Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet *24*, 175-179.
Hoffman, M.M., Buske, O.J., Wang, J., Weng, Z., Bilmes, J.A., and Noble, W.S. (2012). Unsupervised pattern discovery in human chromatin structure through genomic segmentation. Nat Methods *9*, 473-476.

Hofweber, M., Hutten, S., Bourgeois, B., Spreitzer, E., Niedner-Boblenz, A., Schifferer, M., Ruepp, M.D., Simons, M., Niessing, D., Madl, T., *et al.* (2018). Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation. Cell *173*, 706-719 e713.
Jungmichel, S., Rosenthal, F., Altmeyer, M., Lukas, J., Hottiger, M.O., and Nielsen, M.L. (2013). Proteome-wide identification of poly(ADP-Ribosyl)ation targets in different genotoxic stress responses. Mol Cell *52*, 272-285.
Kamelgarn, M., Chen, J., Kuang, L., Jin, H., Kasarskis, E.J., and Zhu, H. (2018). ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay. Proc Natl Acad Sci U S A *115*, E11904-E11913.
Kanoh, Y., Matsumoto, S., Fukatsu, R., Kakusho, N., Kono, N., Renard-Guillet, C., Masuda, K., Iida, K., Nagasawa, K., Shirahige, K., *et al.* (2015). Rif1 binds to G quadruplexes and suppresses replication over long distances. Nat Struct Mol Biol *22*, 889-897.
Kawaguchi, T., Rollins, M.G., Moinpour, M., Morera, A.A., Ebmeier, C.C., Old, W.M., and Schwartz, J.C. (2020). Changes to the TDP-43 and FUS Interactomes Induced by DNA Damage. J Proteome Res *19*, 360-370.
Kim, S.H., Stiles, S.G., Feichtmeier, J.M., Ramesh, N., Zhan, L., Scalf, M.A., Smith, L.M., Pandey, U.B., and Tibbetts, R.S. (2018). Mutation-dependent aggregation and toxicity in a Drosophila model for UBQLN2-associated ALS. Hum Mol Genet *27*, 322-337.
Kim, S.H., Trinh, A.T., Larsen, M.C., Mastrocola, A.S., Jefcoate, C.R., Bushel, P.R., and Tibbetts, R.S. (2016). Tunable regulation of CREB DNA binding activity couples genotoxic stress response and metabolism. Nucleic acids research *44*, 9667-9680.
Koren, A., Polak, P., Nemesh, J., Michaelson, J.J., Sebat, J., Sunyaev, S.R., and McCarroll, S.A. (2012). Differential relationship of DNA replication timing to different forms of human mutation and variation. Am J Hum Genet *91*, 1033-1040.
Kroschwald, S., Maharana, S., Mateju, D., Malinovska, L., Nuske, E., Poser, I., Richter, D., and Alberti, S. (2015). Promiscuous interactions and protein disaggregases determine the material state of stress-inducible RNP granules. Elife *4*, e06807.
Kroschwald, S., Maharana, S., and Simon, A. (2017). Hexanediol: a chemical probe to investigate the material properties of membrane-less compartments. Matters *3*, e201702000010.
Kuroda, M., Sok, J., Webb, L., Baechtold, H., Urano, F., Yin, Y., Chung, P., de Rooij, D.G., Akhmedov, A., Ashley, T., *et al.* (2000). Male sterility and enhanced radiation sensitivity in TLS(-/-) mice. EMBO J *19*, 453-462.
Kwiatkowski, T.J., Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T., *et al.* (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science *323*, 1205-1208.
Kwon, I., Kato, M., Xiang, S., Wu, L., Theodoropoulos, P., Mirzaei, H., Han, T., Xie, S., Corden, J.L., and McKnight, S.L. (2013). Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. Cell *155*, 1049-1060.
Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. Nat Methods *9*, 357-359.
Li, Y.R., King, O.D., Shorter, J., and Gitler, A.D. (2013). Stress granules as crucibles of ALS pathogenesis. J Cell Biol *201*, 361-372.
Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics *30*, 923-930.

Ling, S.C., Dastidar, S.G., Tokunaga, S., Ho, W.Y., Lim, K., Ilieva, H., Parone, P.A., Tyan, S.H., Tse, T.M., Chang, J.C., *et al.* (2019). Overriding FUS autoregulation in mice triggers gain-of-toxic dysfunctions in RNA metabolism and autophagy-lysosome axis. Elife *8*.
Liu, F., Ren, C., Li, H., Zhou, P., Bo, X., and Shu, W. (2016). De novo identification of replication-timing domains in the human genome by deep learning. Bioinformatics *32*, 641-649.
Lopez-Contreras, A.J., Ruppen, I., Nieto-Soler, M., Murga, M., Rodriguez-Acebes, S., Remeseiro, S., Rodrigo-Perez, S., Rojas, A.M., Mendez, J., Munoz, J., *et al.* (2013). A proteomic characterization of factors enriched at nascent DNA molecules. Cell Rep *3*, 1105-1116.
Lopez-Erauskin, J., Tadokoro, T., Baughn, M.W., Myers, B., McAlonis-Downes, M., Chillon-Marinas, C., Asiaban, J.N., Artates, J., Bui, A.T., Vetto, A.P., *et al.* (2018). ALS/FTD-Linked Mutation in FUS Suppresses Intra-axonal Protein Synthesis and Drives Disease Without Nuclear Loss-of-Function of FUS. Neuron *100*, 816-830 e817.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol *15*, 550.
Marchal, C., Sasaki, T., Vera, D., Wilson, K., Sima, J., Rivera-Mulia, J.C., Trevilla-Garcia, C., Nogues, C., Nafie, E., and Gilbert, D.M. (2018). Genome-wide analysis of replication timing by next-generation sequencing with E/L Repli-seq. Nat Protoc *13*, 819-839.
Martinez-Macias, M.I., Moore, D.A., Green, R.L., Gomez-Herreros, F., Naumann, M., Hermann, A., Van Damme, P., Hafezparast, M., and Caldecott, K.W. (2019). FUS (fused in sarcoma) is a component of the cellular response to topoisomerase I-induced DNA breakage and transcriptional stress. Life Sci Alliance *2*.
Mastrocola, A.S., Kim, S.H., Trinh, A.T., Rodenkirch, L.A., and Tibbetts, R.S. (2013). The RNA-binding protein fused in sarcoma (FUS) functions downstream of poly(ADP-ribose) polymerase (PARP) in response to DNA damage. J Biol Chem *288*, 24731-24741.
Mattarocci, S., Hafner, L., Lezaja, A., Shyian, M., and Shore, D. (2016). Rif1: A Conserved Regulator of DNA Replication and Repair Hijacked by Telomeres in Yeasts. Front Genet *7*, 45.
McQuin, C., Goodman, A., Chernyshev, V., Kamentsky, L., Cimini, B.A., Karhohs, K.W., Doan, M., Ding, L., Rafelski, S.M., Thirstrup, D., *et al.* (2018). CellProfiler 3.0: Next-generation image processing for biology. PLoS Biol *16*, e2005970.
Mirman, Z., Lottersberger, F., Takai, H., Kibe, T., Gong, Y., Takai, K., Bianchi, A., Zimmermann, M., Durocher, D., and de Lange, T. (2018). 53BP1-RIF1-shieldin counteracts DSB resection through CST- and Polalpha-dependent fill-in. Nature *560*, 112-116.
Mohammed, H., Taylor, C., Brown, G.D., Papachristou, E.K., Carroll, J.S., and D'Santos, C.S. (2016). Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. Nat Protoc *11*, 316-326.
Noordermeer, S.M., Adam, S., Setiaputra, D., Barazas, M., Pettitt, S.J., Ling, A.K., Olivieri, M., Alvarez-Quilon, A., Moatti, N., Zimmermann, M., *et al.* (2018). The shieldin complex mediates 53BP1-dependent DNA repair. Nature *560*, 117-121.
Patel, A., Lee, H.O., Jawerth, L., Maharana, S., Jahnel, M., Hein, M.Y., Stoynov, S., Mahamid, J., Saha, S., Franzmann, T.M., *et al.* (2015). A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell *162*, 1066-1077.
Peskett, T.R., Rau, F., O'Driscoll, J., Patani, R., Lowe, A.R., and Saibil, H.R. (2018). A Liquid to Solid Phase Transition Underlying Pathological Huntingtin Exon1 Aggregation. Mol Cell *70*, 588-601 e586.
Qamar, S., Wang, G., Randle, S.J., Ruggeri, F.S., Varela, J.A., Lin, J.Q., Phillips, E.C., Miyashita, A., Williams, D., Strohl, F., *et al.* (2018). FUS Phase Separation Is Modulated by a

Molecular Chaperone and Methylation of Arginine Cation-pi Interactions. Cell *173*, 720-734 e715.
Rabbitts, T.H., Forster, A., Larson, R., and Nathan, P. (1993). Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet *4*, 175-180.
Ramirez, F., Ryan, D.P., Gruning, B., Bhardwaj, V., Kilpert, F., Richter, A.S., Heyne, S., Dundar, F., and Manke, T. (2016). deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic acids research *44*, W160-165.
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nat Protoc *8*, 2281-2308.
Rulten, S.L., Rotheray, A., Green, R.L., Grundy, G.J., Moore, D.A., Gomez-Herreros, F., Hafezparast, M., and Caldecott, K.W. (2014). PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-associated protein FUS/TLS to sites of oxidative DNA damage. Nucleic acids research *42*, 307-314.
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., *et al.* (2012). Fiji: an open-source platform for biological-image analysis. Nat Methods *9*, 676-682.
Schwartz, J.C., Wang, X., Podell, E.R., and Cech, T.R. (2013). RNA seeds higher-order assembly of FUS protein. Cell Rep *5*, 918-925.
Sergushichev, A.A. (2016). An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. bioRxiv, 060012.
Shang, Y., and Huang, E.J. (2016). Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Brain Res *1647*, 65-78.
Shortreed, M.R., Wenger, C.D., Frey, B.L., Sheynkman, G.M., Scalf, M., Keller, M.P., Attie, A.D., and Smith, L.M. (2015). Global Identification of Protein Post-translational Modifications in a Single-Pass Database Search. J Proteome Res *14*, 4714-4720.
Silverman, J., Takai, H., Buonomo, S.B., Eisenhaber, F., and de Lange, T. (2004). Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 53BP1 and functions in the S-phase checkpoint. Genes Dev *18*, 2108-2119.
Sima, J., Chakraborty, A., Dileep, V., Michalski, M., Klein, K.N., Holcomb, N.P., Turner, J.L., Paulsen, M.T., Rivera-Mulia, J.C., Trevilla-Garcia, C., *et al.* (2018). Identifying cis Elements for Spatiotemporal Control of Mammalian DNA Replication. Cell.
Singatulina, A.S., Hamon, L., Sukhanova, M.V., Desforges, B., Joshi, V., Bouhss, A., Lavrik, O.I., and Pastre, D. (2019). PARP-1 Activation Directs FUS to DNA Damage Sites to Form PARG-Reversible Compartments Enriched in Damaged DNA. Cell Rep *27*, 1809-1821 e1805.
Sirbu, B.M., Couch, F.B., Feigerle, J.T., Bhaskara, S., Hiebert, S.W., and Cortez, D. (2011). Analysis of protein dynamics at active, stalled, and collapsed replication forks. Genes Dev *25*, 1320-1327.
Sun, S., Ling, S.C., Qiu, J., Albuquerque, C.P., Zhou, Y., Tokunaga, S., Li, H., Qiu, H., Bui, A., Yeo, G.W., *et al.* (2015). ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat Commun *6*, 6171.
Sun, Z., Diaz, Z., Fang, X., Hart, M.P., Chesi, A., Shorter, J., and Gitler, A.D. (2011). Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol *9*, e1000614.
Tan, A.Y., and Manley, J.L. (2009). The TET family of proteins: functions and roles in disease. J Mol Cell Biol *1*, 82-92.

Tonzi, P., Yin, Y., Lee, C.W.T., Rothenberg, E., and Huang, T.T. (2018). Translesion polymerase kappa-dependent DNA synthesis underlies replication fork recovery. Elife *7*.
Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., *et al.* (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science *323*, 1208-1211.
Wang, H., Guo, W., Mitra, J., Hegde, P.M., Vandoorne, T., Eckelmann, B.J., Mitra, S., Tomkinson, A.E., Van Den Bosch, L., and Hegde, M.L. (2018). Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in Amyotrophic Lateral Sclerosis. Nat Commun *9*, 3683.
Wang, W.Y., Pan, L., Su, S.C., Quinn, E.J., Sasaki, M., Jimenez, J.C., Mackenzie, I.R., Huang, E.J., and Tsai, L.H. (2013). Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat Neurosci *16*, 1383-1391.
Wisniewski, J.R., Zougman, A., Nagaraj, N., and Mann, M. (2009). Universal sample preparation method for proteome analysis. Nat Methods *6*, 359-362.
Woodfine, K., Fiegler, H., Beare, D.M., Collins, J.E., McCann, O.T., Young, B.D., Debernardi, S., Mott, R., Dunham, I., and Carter, N.P. (2004). Replication timing of the human genome. Hum Mol Genet *13*, 191-202.
Xu, D., Muniandy, P., Leo, E., Yin, J., Thangavel, S., Shen, X., Ii, M., Agama, K., Guo, R., Fox, D., 3rd, *et al.* (2010). Rif1 provides a new DNA-binding interface for the Bloom syndrome complex to maintain normal replication. EMBO J *29*, 3140-3155.
Yamazaki, S., Ishii, A., Kanoh, Y., Oda, M., Nishito, Y., and Masai, H. (2012). Rif1 regulates the replication timing domains on the human genome. EMBO J *31*, 3667-3677.
Yoshizawa, T., Ali, R., Jiou, J., Fung, H.Y.J., Burke, K.A., Kim, S.J., Lin, Y., Peeples, W.B., Saltzberg, D., Soniat, M., *et al.* (2018). Nuclear Import Receptor Inhibits Phase Separation of FUS through Binding to Multiple Sites. Cell *173*, 693-705 e622.
Yu, G., Wang, L.G., Han, Y., and He, Q.Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. Omics *16*, 284-287.
Zinszner, H., Albalat, R., and Ron, D. (1994). A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev *8*, 2513-2526.

Figure 1


A
FUS
sgRNA1
sgRNA2
e4-Fwd
e4-Rev
49bp
sgRNA2
CCAGGGATATGGCTCGACTGGCG...AGAGCTCCCAATCGTCTTACGGG
GGTCCCTATACCGAGCTGACCGC...TCTCGAGGGTTAGCAGAATGCCC
4041
sgRNA1
4089
B
FUS+/+
FUS-/-
U2OS
Cl.26
Cl.46
Cl.65
Cl.110
EWSR1
TAF15
FUS
TUBULIN
C
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
FUS
KU70
D
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
E
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
P<0.000001
P=0.000766
P<0.000001
P=0.000141
P<0.000001
P=0.003235
P=0.001921
P=0.742879
P
P
Cell proliferation
day
0
10
20
30
40
0
1
2
3
4
5

Figure 2


A
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
Double thymidine release (hrs)
12
10
8
6
4
2
0
ASN
DNA Content
B
Edu Incorporation
Cell Frequency
S
18.0
G1
73.7
G2_M
6.89
S
13.9
G1
76.6
G2_M
8.31
S
22.4
G1
67.0
G2_M
9.98
S
0.14
G1
78.5
G2_M
10.4
S
0.16
G1
80.5
G2_M
9.98
S
0.19
G1
81.0
G2_M
8.79
S
73.6
G1
16.7
G2_M
8.27
S
58.6
G1
29.9
G2_M
7.44
S
78.5
G1
12.8
G2_M
6.62
S
4.95
G1
69.2
G2_M
23.9
S
14.5
G1
40.1
G2_M
43.6
S
6.99
G1
54.3
G2_M
36.5

Figure 3


A
DNA Replication
enrichment score
rank
B
group
WT
KO
RE
cluster
1
2
3
GINS4
RFC4
MCM4
TIMELESS
RFC5
WRN
DTL
ORC3
RRM2
TOP1
CDC45
CDC25A
DNAJA3
NFIB
POLQ
FANCM
GINS1
POLE2
CINP
POLD1
EXO1
R1 R2 R3
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
C
DNA Replication Related Genes
Normalized Counts
Sample
WT
KO
RE
WRN
GINS4
RFC4
TIMELESS
MCM4
ORC3
RRM2
RFC5
DTL
CDC45
CDC25A
DNAJA3
TOP1
D
DNA Repair
enrichment score
rank
E
group
WT
KO
RE
cluster
1
2
RFC5
USP10
GTF2H3
GINS4
TDG
RFC4
TRIP13
RAD52
ACTL6A
TCEA1
CHEK2
UBE2T
MGMT
ESCO2
WRN
FANCD2
PRKDC
FANCA
DTL
POLE2
TDP1
FOXM1
POLQ
RAD51AP1
UHRF1
FANCM
UBE2V2
XRCC3
PPP5C
DMC1
CDC45
ALKBH1
CINP
RUVBL2
ERCC1
REC8
ATXN3
YY1
MTA1
ERCC2
POLD1
EXO1
R1 R2 R3
FUS+/+:Vec
FUS-/-:FUS
FUS-/-:Vec
F
DNA Repair Related Genes
Normalized Counts
Sample
WT
KO
RE
WRN
MGMT
GINS4
PRKDC
RFC4
ACTL6A
FANCD2
FANCA
RAD52
CHEK2
TCEA1
UBE2T
ESCO2
TDG
USP10
TRIP13
GTF2H3
RFC5
DTL

Figure 4


A
micronuclei
Mock
Aph
Percentage
0.0296
0.0002
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
B
Fork Speed:
IdU
CldU
20min
20min
Avg kb/min:
0.83
0.65
0.75
2nd Color Track Length (kb)
C
Restart:
IdU
2mM HU
CldU
20min
4hr
30min
% Stalled Forks
D
EdU
Thymidine
15min
60min
Pulse
Chase
HU
120min
Input
iPOND
Click
FUS
PCNA
H3

Figure 5


A
FUS-/-:FUS(G1)
FUS-/-:FUS(M)
FUS-/-:Vec(G1)
FUS-/-:Vec(M)
FUS+/+:Vec(G1)
FUS+/+:Vec(M)
DNA Content
B
M
G1
M
G1
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
CDC6
CDT1
ORC4
LAMINB1
TUBULIN
Soluble Fraction
Chromatin Fraction

Figure 6


A
Unique peptides 25 50 75
-Log10(p value)
Fold Change(FUS+/+ vs FUS-/-)
PNKP
PRKDC
XRCC5
XRCC1
POLD1
TCEA1
TOP1
XRCC6
HMGB1
PARP1
POLD2
RBBP6
APEX1
HMGB2
FEN1
TOP2A
UHRF1
AQR
SSRP1
XAB2
CDC5L
MCM5
RPA1
NONO
PCNA
TRIM28
SFPQ
SMARCA5
MDC1
BAZ1B
RECQL
USP7
B
Input
IP
FUS-/-
FUS+/+
POLD1
UHRF1
TOP1
FUS
PCNA
Heavy chain
C
Input
IP
FUS+/+
FUS-/-
FUS
FEN1
PCNA
D
FUS + POLD1
FUS + PCNA
FUS + FEN1
PLA
Merged
FUS+/+
FUS-/-
E
FUS+/+
FUS-/-
p=5.5e-14
n=86
n=89
7
3
PLA Counts
POLD1
p < 2.22e-16
n=72
n=87
20.5
2
PCNA
p < 2.22e-16
n=85
n=96
11
3
FEN1

Figure 7


A
FUS+/+
Late S
Early S
Middle S
10μm
FUS-/-(Cl.46)
FUS-/-(Cl.65)
FUS-/-(Cl.110)
B
Early S
Middle S
Late S
FUS+/+
U2OS
49.15
35.93
14.92
FUS-/-
Cl.46
76.17
12.44
11.4
Cl.65
69.23
16.41
14.36
Cl.110
69.34
19.34
11.31
0
25
50
75
100
Percentage(%)
C
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
ASN
4h
6h
8h
Middle S
Early S
Late S
10μm
D
Early S
Middle S
Late S
ASN
FUS+/+:Vec
60.73
29.66
9.6
FUS-/-:Vec
68.6
14.73
16.67
FUS-/-:FUS
56.25
26.42
17.33
4 h
FUS+/+:Vec
54.3
37.1
8.6
FUS-/-:Vec
62.78
25.55
11.67
FUS-/-:FUS
47.18
42.14
10.68
6 h
FUS+/+:Vec
39.45
40.69
19.85
FUS-/-:Vec
65.99
18.37
15.65
FUS-/-:FUS
41.29
39.02
19.7
8 h
FUS+/+:Vec
15.05
41.38
43.57
FUS-/-:Vec
53.57
17.14
29.29
FUS-/-:FUS
17.09
47.64
35.27
0
25
50
75
100
Percentage(%)

Figure 8


A
Replication Timing
Early
Late
Chromosome
B
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
Rep.1
Rep.2
Replication Timing
Chromsome 18 (Mb)
C
FUS+/+:Vec
FUS-/-:FUS
FUS-/-:Vec
R1
R2
1.00 0.98 0.98 0.95 0.89 0.68
0.98 1.00 0.98 0.97 0.91 0.74
0.98 0.98 1.00 0.97 0.92 0.72
0.95 0.97 0.97 1.00 0.94 0.80
0.89 0.91 0.92 0.94 1.00 0.89
0.68 0.74 0.72 0.80 0.89 1.00
D
FUS+/+:Vec vs FUS-/-:Vec
FUS+/+:Vec vs FUS-/-:FUS
Rep.1
Counts
RT Difference
E
FUS+/+:Vec vs FUS-/-:Vec
FUS+/+:Vec vs FUS-/-:FUS
Rep.2
Counts
RT Difference
F
FUS+/+:Vec
FUS-/-:Vec
FUS-/-:FUS
All
Density
Replication Timing
G
Chr. 2
H
Chr. 5
I
Chr. 20

Figure 9


A
Domain ERD MRD LRD
Domain Count
610 995 478
655 1102 559
615 1019 505
FUS+/+:Vec FUS-/-:Vec FUS-/-:FUS
B
Domain ERD MRD LRD
Genome Coverage (%)
40.42 27.13 32.45
40.6 28.91 30.49
40.65 27.91 31.44
FUS+/+:Vec FUS-/-:Vec FUS-/-:FUS
C
FUS+/+:Vec FUS-/-:Vec FUS-/-:FUS
ERD MRD LRD
0.61 0.47
0.76 0.75
0.077 0.0042
Domain Size (bp)
D
FAD-M(9.26)
39.73
60.27
MRD (27.13)
ERD (40.42)
88.64
FAD-L(6.53)
21.85
LRD (32.45)
11.36
78.15
FAD-E(4.37)
E
FUS+/+:Vec FUS-/-:Vec FUS-/-:FUS
RT
-500kb center 500kb
FAD-E
FAD-M
FAD-L
F
FAD-E FAD-M FAD-L
gene distance (bp)
G
FAD-E ERD_U-2 OS
gene distance (bp)
H
FAD-M MRD_U-2 OS
gene distance (bp)
I
FAD-L LRD_U-2 OS
gene distance (bp)
J
GO Analysis of FADs genes(BF)
membrane disruption in other organism
innate immune response in mucosa
synaptic transmission, glutamatergic
G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
cyclic-nucleotide-mediated signaling
detection of chemical stimulus involved in sensory perception of smell
detection of chemical stimulus involved in sensory perception
positive regulation of nervous system development
regulation of neuron projection development
regulation of membrane potential
regulation of synapse assembly
retinal ganglion cell axon guidance
FAD-E (933) FAD-M (1192) FAD-L (369)
pvalue
GeneRatio
K
GO Analysis of FADs genes(MF)
sulfuric ester hydrolase activity
arylsulfatase activity
olfactory receptor activity
G-protein coupled amine receptor activity
sodium:proton antiporter activity
cation:cation antiporter activity
monovalent cation:proton antiporter activity
ion gated channel activity
gated channel activity
ion channel activity
substrate-specific channel activity
oxygen carrier activity
FAD-E (926) FAD-M (1169) FAD-L (362)
pvalue
GeneRatio

Figure 10


A
FUS
DAPI
FUS/DAPI
FUS+/+
FUS-/-
B
FUS
DAPI
FUS/DAPI
Mock
Rnase
Benzonase
C
FUS
DAPI
FUS/DAPI
Mock
3%, 30''
3%, 5'
3%, 20'

Supp.Figure 1



Supp.Figure 2



Supp.Figure 3



Supp.Figure 4



Supp.Figure 5



Supp.Figure 6



Supp.Figure 7



Supp.Figure 8



Supp.Figure 9